Specificity of mutations induced by methyl methanesulfonate in mismatch repair-deficient human cancer cell lines

被引:39
作者
Glaab, WE
Tindall, KR
Skopek, TR
机构
[1] Merck Res Labs, Dept Genet & Cellular Toxicol, W Point, PA 19486 USA
[2] NIEHS, Lab Environm Carcinogenesis & Mutagenesis, Res Triangle Pk, NC 27709 USA
关键词
mismatch repair; HPRT; methyl methanesulfonate; mutational specificity;
D O I
10.1016/S0027-5107(99)00091-3
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Recently, we showed that the cytotoxic and mutagenic response in human cells to the model S(N)2 alkylating agent methyl methanesulfonate (MMS) can be modulated by the mismatch repair (MMR) pathway. That is, human cancer cell lines defective in MMR are more resistant to the cytotoxic effects of MMS exposure and suffer more induced mutations at the HPRT locus than MMR-proficient cell lines. Since MMS produces little O-6-methylguanine (O-6-meG), the observed hypermutability and resistance to cytotoxicity in MMR-defective cells likely results from lesions other than O-6-meG. MMS produces a high yield of N7-methylguanine (N7-meG) and N3-methyladenine (N3-meA), which can lead to the formation of promutagenic abasic sites, and these lesions may be responsible for the observed cytotoxic and/or mutagenic effects of MMS. To further investigate the mechanism of MMS mutagenesis, two MMR-defective human cancer cell lines were treated with MMS and the frequency and the types of mutations produced at the HPRT locus were determined. MMS treatment (1.5 mM) produced a 1.6- and a 2.2-fold increase in mutations above spontaneous levels in HCT116 and DLD-1 cell lines, respectively. An average 3.7-fold increase in transversion mutations was observed, which accounted for greater than one-third of all induced mutations in both cell lines. In contrast, an average 1.6-fold increase was seen among transition mutations (the class expected from O-alkylation products). Since transversion mutations are not produced by O-6-meG, these findings suggest that abasic sites may be the lesion responsible for a large proportion of MMS mutagenicity in MMR-defective cells. Furthermore, these data suggest the MMS-induced damage, either abasic site-inducing base alterations (i.e., N7-meG and N3-meA) or the resulting abasic sites themselves, may be substrates for recognition and/or repair by MMR proteins. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:67 / 78
页数:12
相关论文
共 55 条
  • [1] ANDREW SE, 1998, P NATL ACAD SCI USA, V95, P6443
  • [2] AQUILINA G, 1995, CANCER RES, V55, P2569
  • [3] Physical interaction between components of DNA mismatch repair and nucleotide excision repair
    Bertrand, P
    Tishkoff, DX
    Filosi, N
    Dasgupta, R
    Kolodner, RD
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (24) : 14278 - 14283
  • [4] MOLECULAR ANALYSIS OF MUTATIONS IN MUTATOR COLORECTAL-CARCINOMA CELL-LINES
    BHATTACHARYYA, NP
    GANESH, A
    PHEAR, G
    RICHARDS, B
    SKANDALIS, A
    MEUTH, M
    [J]. HUMAN MOLECULAR GENETICS, 1995, 4 (11) : 2057 - 2064
  • [5] MUTATOR PHENOTYPES IN HUMAN COLORECTAL-CARCINOMA CELL-LINES
    BHATTACHARYYA, NP
    SKANDALIS, A
    GANESH, A
    GRODEN, J
    MEUTH, M
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (14) : 6319 - 6323
  • [6] Impairment of proliferating cell nuclear antigen-dependent apurinic/apyrimidinic site repair on linear DNA
    Biade, S
    Sobol, RW
    Wilson, SH
    Matsumoto, Y
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (02) : 898 - 902
  • [7] BRANCH P, 1995, CANCER RES, V55, P2304
  • [8] BRONSTEIN SM, 1991, CANCER RES, V51, P5188
  • [9] Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N'-nitro-N-nitrosoguanidine
    Carethers, JM
    Hawn, MT
    Chauhan, DP
    Luce, MC
    Marra, G
    Koi, M
    Boland, CR
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (01) : 199 - 206
  • [10] Databases and software for the analysis of mutations in the human p53 gene, the human hprt gene and the lacZ gene in transgenic rodents
    Cariello, NF
    Douglas, GR
    Soussi, T
    [J]. NUCLEIC ACIDS RESEARCH, 1996, 24 (01) : 119 - 120